These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12390732)

  • 1. [Effect of anti-HPV16 E6-ribozyme on the sensitivity of cervical carcinoma cell line to chemotherapy].
    Rao ZG; Zhang JR; Zheng YF; Zhou H; Qu LG
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Apr; 22(4):316-9. PubMed ID: 12390732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radiation sensitizing effect of anti HPV16E6-ribozyme on cervical carcinoma cell line].
    Rao ZG; Zhang JR; Zheng YF; Zhou H; Qu LH
    Ai Zheng; 2002 Feb; 21(2):149-52. PubMed ID: 12479064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anti-HPV16 E6-ribozyme on the proliferation and apoptosis of human cervical cancer cell line CaSKi.
    Zheng YF; Rao ZG; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Jun; 22(6):496-8. PubMed ID: 12297466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme targeted on HPV16E6 mRNA induced apoptosis on human cervical carcinoma CaSKi cells.
    Zheng YF; Zhang JR
    Ai Zheng; 2003 May; 22(5):458-62. PubMed ID: 12753702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anti-HPV16E6-ribozyme on phenotype and gene expression of a cervical cancer cell line.
    Zheng Y; Zhang J; Qu L
    Chin Med J (Engl); 2002 Oct; 115(10):1501-6. PubMed ID: 12490096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of anti-HPV16 E6-ribozyme on invasiveness of cervical carcinoma cell line CaSKi and vascular endothelial growth factor expression].
    Liu K; Wang LL; Zheng YF; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):529-32. PubMed ID: 15151824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi].
    Liu K; Wang LL; Sun F; Zheng YF; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1367-72. PubMed ID: 15604060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effect of RNA interference on expression of HPV16 E6 oncogene in cervical cancer cell line CaSki].
    Niu XY; Peng ZL; Wang H
    Ai Zheng; 2004 Nov; 23(11):1257-62. PubMed ID: 15522169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of siRNA inhibiting HPV16 E6 gene expression on proliferation and cell cycle of cervical cancer cell line CaSki].
    Guan LL; Peng ZL; Niu XY; Wang HJ; Wang DQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 39(1):10-4. PubMed ID: 18390189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of HPV16 E6 oncogene in cervical cancer by RNA interference].
    Niu XY; Peng ZL; Duan WQ; Wang H; Chen YY; Fan YJ; Cheng YF; Qian XL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):14-8. PubMed ID: 16468632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reversal effect of antisense RNA targeting human papillomavirus 16 (HPV16) E6E7 on malignancy of human cervical cancer cell line SiHa].
    Sima N; Wang W; Xu Q; Tian X; Luo AY; Lu YP; Wang SX; Ma D
    Ai Zheng; 2007 Jan; 26(1):26-31. PubMed ID: 17222363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antisense targeting to human papillomavirus 18 E6/E7 affects the proliferation and apoptosis of human cervical carcinoma: an in vitro experiment with HeLa cells].
    Sima N; Kong DB; Wang W; Lu YP; Wang SX; Ma D
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1618-21. PubMed ID: 17803852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.
    Mathur RS; Mathur SP
    Gynecol Oncol; 2005 Apr; 97(1):206-13. PubMed ID: 15790460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
    Hampson L; Kitchener HC; Hampson IN
    Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of SNCG transfection on the effectiveness of anti-tumor drugs in PC-3 cell lines].
    Chen JL; Wang B; Zhang LR; He BS; Pan YQ; Zeng QD; Jiang HX; Wang SK
    Zhonghua Nan Ke Xue; 2008 Dec; 14(12):1077-82. PubMed ID: 19157226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.
    Ahn WS; Bae SM; Lee KH; Lee JM; Namkoong SE; Chun HJ; Kim CK; Kim YW
    Gynecol Oncol; 2004 Feb; 92(2):611-21. PubMed ID: 14766255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
    Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
    Koivusalo R; Krausz E; Helenius H; Hietanen S
    Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.